Disease

Ehlers-Danlos Syndrome

Late-stage therapeutic developmentEmerging research

MeSHEhlers-Danlos Syndrome

Publications

Clinical trials

2017

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

Research2017-02-01American journal of medical genetics. Part C, Seminars in medical genetics

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q1 2029.

Upcoming Milestones

Q1 2029A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome

Major developments

Upcoming trial readoutImportant

A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome

Results expected Q1 20292025-08-24

Clinical Milestones1View

Results expected 1

2025-08-24A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos SyndromeResults expected Q1 2029

Activity timeline1

2025-08-24ClinicalA Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos SyndromeResults expected Q1 2029

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome

Phase 3 · Recruiting · Acer Therapeutics Inc.

Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers

Phase 4 · Active, not recruiting · University of Calgary

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.

Phase 3 · Completed · Assistance Publique - Hôpitaux de Paris

Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome

Phase 4 · Completed · Assistance Publique - Hôpitaux de Paris

Recruiting

A Phase 3 Randomized, Double-Blind, Decentralized Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in the Treatment of Patients With COL3A1-Positive Vascular Ehlers-Danlos Syndrome

Phase 3 · Recruiting · Acer Therapeutics Inc.

Recently completed

Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.

Phase 3 · Completed · Assistance Publique - Hôpitaux de Paris

IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients

N/A · Completed · Bispebjerg Hospital

Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome

Phase 4 · Completed · Assistance Publique - Hôpitaux de Paris

A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome

Phase 2 · Completed · National Human Genome Research Institute (NHGRI)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

American journal of medical genetics. Part C, Seminars in medical genetics · 2017 · 334 cites

Recent publications

Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.

American journal of medical genetics. Part C, Seminars in medical genetics · 2017 · 334 cites

Leading journals1

American journal of medical genetics. Part C, Seminars in medical genetics1

Leading researchers7

Berglund B1
Castori M1
Cohen H1
Grahame R1
Kazkaz H1
Levy H1
Tinkle B1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.

Identifiers

MeSHEhlers-Danlos Syndrome

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.